The Effects of the CF Carrier State on the Kidneys and Pancreas

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Philip Polgreen
Study ID
NCT05474417
Status
Recruiting
Apply to this trial

Conditions

  • Carrier State
  • Kidney Diseases
  • Pancreatic Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.

Key Dates

Start date
Dec 20, 2021
Status verified
Jan 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
1,250 participants (estimated)

Arms

  • Arm: Cystic Fibrosis Carrier Group
    Participants who have been identified as Cystic Fibrosis Carriers via previous genetic testing.
  • Arm: Control Group
    Participants who have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.

Primary Outcome Measure

Comparison of Glucose Values [ Time Frame: At baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Iowa Hospitals and ClinicsIowa CityIowa52242
Shelby L Francis, PhD
[email protected]
319-678-8037

Find similar trials in Iowa City, IA

By research site
University of Iowa Hospitals and Clinics· Iowa City, IA

Related Studies